ContraVir Pharmaceuticals to Present CRV431 Phase 1 Data at the International Liver Congress™
A Phase 1 Single Ascending Dose Study of CRV431
Poster presentation number: FRI-171
Authors: Danielle Armas1,
Date: Friday April 12, 2019
CRV431 is a clinical stage cycliphilin inhibitor. Its primary biochemical action is inhibition of cyclophilin isomerase activity, which is known to play a key role in protein folding. In non-clinical, experimental models of NASH, CRV431 reduced fibrosis scores and hepatocellular carcinoma (HCC) tumor burden. In addition, CRV431 has also shown activity against certain viruses including HBV, HCV, and HIV-1. CRV431 has demonstrated an ability to reduce multiple markers of HBV infection including reductions in DNA, HBsAg, HBeAg, and HBV uptake by liver cells. These multiple modes of action may play an important role in the overall treatment of liver disease, from triggering events through to end-stage liver disease. CRV431 has completed phase 1 human clinical trials.
ContraVir is a biopharmaceutical company focused on the development of targeted therapies for liver disease arising from non-alcoholic steatohepatitis (NASH) and chronic hepatitis B, C and D viruses (HBV, HVC, HDV). The company’s lead drug candidate is CRV431, a novel cyclophilin inhibitor. In vitro and in vivo studies have thus far demonstrated that CRV431 reduces liver fibrosis and hepatocellular carcinoma tumor burden. CRV431 is also a host-targeting antiviral that reduces important viral proteins, such as those involved in host cell entry and viral replication. For more information, please visit www.contravir.com.
Forward Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimated,” and “intend,” among others. These forward-looking statements are based on ContraVir’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; uncertainties with respect to lengthy and expensive clinical trials, that results of earlier studies and trials may not be predictive of future trial results; uncertainties of government or third party payer reimbursement; limited sales and marketing efforts and dependence upon third parties; and risks related to failure to obtain
For further information, please contact:
ContraVir Investor Relations
Source: ContraVir Pharmaceuticals Inc.